StockData

Allarity Therapeutics vs Inovio Pharmaceuticals

ALLR and INO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ALLR and INO compare

Inovio Pharmaceuticals is the larger company, worth 10 times as much as Allarity Therapeutics ($145M against $13.9M).

Inovio Pharmaceuticals scores higher on the StockData Score (4 against 1 for Allarity Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricALLRINO
Size and price
Market cap$13.9M$145M
Share price$0.875$1.40
Change, 1 year−26.5%−28.2%
Change, 5 years–−98.4%
Beta (5Y)1.41−0.03
Employees827
StockData Score
Total score14 (better)
Valuation score00
Growth score00
Performance score00
Health score14 (better)
Dividend score00
Valuation
P/B3.9× (better)33.1×
FCF yield–−55.8%
Growth
Revenue growth (TTM)–−100%
Revenue growth, 5Y average–−61.2%
Profitability
Return on equity−157% (better)−410%
Return on invested capital−957%–
Financial health
Debt / equity5.90 (better)0.00
Interest coverage−10.1×–
Current ratio1.11 (better)1.00
Altman Z-score−6.64 (better)−55.55
Piotroski F-score4 (better)1
Dividends and buybacks
Buyback yield6.4% (better)−26.3%
Shareholder yield6.4% (better)−26.3%
Ownership
Held by institutions8.1%31.7%
Held by insiders6.3%0.38%
Short interest, % of float1.5%21.5%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.